Acne Vulgaris Pipeline Analysis Demonstrates Novel 22+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight's, "Acne Vulgaris Pipeline Insight, 2023," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the Acne Vulgaris pipeline drug profiles, including Acne Vulgaris clinical trials and nonclinical stage products. It also covers the Acne Vulgaris pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Acne Vulgaris Emerging Drugs, the Acne Vulgaris pipeline analysis report provides a 360° view of the Acne Vulgaris pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acne Vulgaris pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Acne Vulgaris Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Acne Vulgaris clinical trials studies, Acne Vulgaris NDA approvals (if any), and product development activities comprising the technology, Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Acne Vulgaris Pipeline Report

• Over 22+ Acne Vulgaris companies are evaluating 22+ Acne Vulgaris pipeline therapies in various stages of development, and their anticipated acceptance in the Acne Vulgaris market would significantly increase market revenue.

• The leading Acne Vulgaris Companies includes Novan, Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio, Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea, Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.

• Promising Acne Vulgaris Pipeline Therapies includes BOS-356, Imsidolimab, Aminolevulinic acid (ALA), IDP-126, BTX 1503, FCD 105, GT 20029, and others.

• The Acne Vulgaris Companies and academics that are working to assess challenges and seek opportunities that could influence Acne Vulgaris R&D. The Acne Vulgaris pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

Explore more information on the latest breakthroughs in the A Acne Vulgaris treatment landscape of the report, visit here Acne Vulgaris Pipeline Outlook @ https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acne Vulgaris Overview

Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne may appear in adolescence, and it persists through the early thirties. Acne is more common in males than in females. Urban populations are more affected than rural populations. About 20% of the affected individuals develop severe acne, which results in scarring.

Recent Developmental Activities in the Acne Vulgaris Treatment Landscape

• In December 2020, Sol-Gel Technologies announced that their New Drug Application (NDA) for Twyneo for the treatment of acne vulgaris, has been accepted for filing by the U.S. Food and Drug Administration (FDA).

• In January 2021, Eligo Bioscience SA (Eligo) announced that it had entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutics for strain-specific microbiome modulation.

• BioPharmX is developing a novel, proprietary topical minocycline gel formulation (BPX-01) for the treatment of acne vulgaris. The product is the first candidate from the company's anhydrous hydrophilic topical delivery system and in our formulation, the minocycline is completely solubilized. The formulation is currently in clinical development for patients with inflammatory lesions of acne vulgaris.

• In April 2021, Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced that the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients enrolment and successfully dosed in China.

• In April 2021, Bausch Health Companies Inc., and its dermatology business, Ortho Dermatologics, announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating its investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical, to treat acne vulgaris in patients nine years of age and older.

Find the information related to the Acne Vulgaris emerging therapies and companies, visit here Acne Vulgaris Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acne Vulgaris Emerging Drugs Profile

• IDP126: Bausch Health Americas, Inc.
A fixed dose combination of adapalene, benzoyl peroxide and clindamycin phosphate gel formulation, designated as IDP 126, is being developed by Bausch. In June 2021, Ortho Dermatologics, a Bausch Health Company, announced results from its second phase III trial investigating the safety and efficacy of IDP-126 (Ortho Dermatologics)) for the treatment of acne vulgaris in patients 9 years and older. This study, a phase III, multicenter, randomized, double-blind, vehicle-controlled trial, met all coprimary endpoints by week 12. The endpoints were the absolute change from baseline in inflammatory lesion count and noninflammatory lesion count, and percentage of patients who achieved treatment success. The treatment success was defined as clear or almost clear skin in the Evaluator's Global Severity Score (EGSS).

• DMT310: Dermata Therapeutics
DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties.Currently it is being evaluated in Phase II stage of development to treat acne vulgaris.

Acne Vulgaris Pipeline Therapeutics Assessment
There are approx. 22+ key companies which are developing the therapies for Acne Vulgaris. The companies which have their Acne vulgaris drug candidates in the most advanced stage, i.e. Phase III include, Bausch Health Americas, Inc.

For further information, refer to the detailed Acne Vulgaris Pipeline report, visit here for Acne Vulgaris Treatment Landscape @ https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acne Vulgaris Pipeline Report

• Coverage- Global

• Acne Vulgaris Companies- Novan, Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio, Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea, Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.

• Acne Vulgaris Pipeline Therapies- BOS-356, Imsidolimab, Aminolevulinic acid (ALA), IDP-126, BTX 1503, FCD 105, GT 20029, and others

• Acne Vulgaris Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Acne Vulgaris Market Drivers and Acne Vulgaris Market Barriers, click here @ Acne Vulgaris Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Acne vulgaris: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. IDP126: Bausch Health Americas, Inc.
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. DMT310: Dermata Therapeutics
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. ORG101: Origimm Biotechnology
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Acne vulgaris Key Companies
17. Acne vulgaris Key Products
18. Acne vulgaris- Unmet Needs
19. Acne vulgaris- Market Drivers and Barriers
20. Acne vulgaris- Future Perspectives and Conclusion
21. Acne vulgaris Analyst Views
22. Acne vulgaris Key Companies
23. Appendix

Got Queries? Find out the related information on Acne Vulgaris Mergers and acquisitions, Acne Vulgaris Licensing Activities @ Acne Vulgaris Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.